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Abstract: Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new
cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen
Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for
new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions
of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques
provide single-cell analysis which reduces experimental time and the cost of reagents, and have been
extremely useful for gaining insight into monitoring microorganisms. This review outlines the field
of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics,
research methods, and drug discovery platforms. The practices of microfluidics have promising
future applications for diagnosing and treating TB.
Keywords: tuberculosis; Mycobacterium; diagnostics; drug discovery; antibiotics; antimicrobial
resistance; microfluidics; single-cell analysis; bioengineered models
1. Introduction
1.1. Tuberculosis and Its Global Health Threat
Mycobacterium tuberculosis is the causative agent of the human pulmonary infection
tuberculosis (TB). TB is the second leading infectious killer since the global COVID-19
pandemic. The World Health Organisation (WHO) estimates that 1.5 million people died
from TB in 2020 [1]. Despite most TB strains being treatable with antibiotics, some of
the key medical challenges include achieving rapid diagnostics, the rise of multidrug-
resistant TB, and the poor treatment efficacy of latent TB. The current recommended
treatment for drug-susceptible TB takes a minimum six-month administration of isoniazid
(INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB) [2]. This first-line
recommendation has failed to adapt in the last thirty-five years despite the increasing
occurrence of drug resistance. Recently, a phase 3 trial provided evidence of a four-month
treatment regimen with rifapentine and moxifloxacin [3]. Additionally, many efforts have
been made to reduce the mycobacterial burden (reducing mortality and transmission),
eradicate persistent mycobacterial populations, and to reduce drug resistance through
various incentives such as END-TB [4] and WHO End TB Strategy 2016–2035 [5]. Research
into the economic burden of TB has revealed a global cost of 983 bn USD from 2015–
2030 if the current health status continues [6]. There is a pressing need for innovative
advancements and applications which combine multidisciplinary research for combating
the looming crisis of TB.
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1.2. Mycobacterium Tuberculosis and the Pathogenesis of TB
M. tuberculosis is a rod-shaped acid-fast-staining bacterium of the Actinomycete fam-
ily [7]. The unique “waxy” cell envelope of M. tuberculosis contains a core composed of
peptidoglycan and the highly branched polysaccharide arabinogalactan. This is covalently
attached to the unique mycolic acids that cover the bacteria with a mycobacterial outer
membrane which allows cellular integrity and virulence [8]. This self-protection permits
the organism to evade the host immune system and prevents antibiotic penetration [8,9].
The molecular pathology by which M. tuberculosis evades the host and causes disease is
complex, involving a dynamic range of immune cells. The organism infects the host after
the inhalation of droplet nuclei spread by aerosolisation from an infected individual, which
then resides in the respiratory tract [10]. There are various types of infection that can mani-
fest from M. tuberculosis in individuals—one where the infection clears, one with an active
infection treated with a course of antibiotics, and one which remains in a latent form [11].
Upon infection, the early innate immune system emerges with an influx of neutrophils,
monocytes, macrophages, and dendritic cells of the lungs [12]. Through phagocytosis, bac-
teria are consumed by alveolar macrophages to form a phagosome and then subsequently
eliminated through the formation of phagolysosomes [13]. However, M. tuberculosis can
avoid this host defence response by persisting in phagosomes and inhibiting lysosome
fusion [13]. The subsequent established intracellular infection and influx of immune cells
which surround the site of infection forms a tuberculous granuloma [14]. The early gran-
uloma (Figure 1) consists of the infected macrophages in the centre, enclosed by foamy
macrophages and other mononucleated cells, and surrounded by lymphocytes [15]. During
the maturation of the granuloma, a fibrous capsule encloses the macrophage centre and
eventually forms necrotic lesions, leading to caseation [14,15].
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Figure 1. Tuberculous granuloma. Encapsulated Mycobacterium tuberculosis surrounded by immune
cells, creating a hypoxic, nutrient-deprived, and nitric oxide environment. Adapted from “Granu-
loma”, by BioRender.com (2020). Retrieved from https://app.biorender.com/biorender-templates,
accessed on 27 September 2021.
Here, M. tuberculosis can survive in a dormancy state known as non-replicating persis-
tence (NRP). The external pressures such as hypoxia, nutrient deprivation, low pH, and
high CO2 created by the hostile host environment induce this survival response of the bac-
teria [16]. The NRP state can relapse into active disease, especially in high-risk groups such
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as immunodeficient individuals, persons infected with human immunodeficiency virus
or undergoing organ and haematologic transplantations [11]. Houben and Dodd (2016)
previously estimated that NRP TB infected approximately 1.7 billion people in 2014 by
generating an annual risk model of infection between 1934 and 2014 [17]. The issue posed
by the ability of NRP M. tuberculosis to effectively hide within the hostile environment
of the granuloma is that not only does the immune system keep the bacteria trapped, it
also physically restricts penetration by antimicrobials, thus protecting M. tuberculosis from
antibiotic activity.
1.3. Current Diagnostics, Research Methods, and Treatment
Early diagnosis and accurate detection of TB infection is essential for effective treat-
ment options, especially in low-income and high-burden countries. Conventional TB
diagnostics include microscopy (Ziehl–Neelsen staining), which provides 22–43% low
sensitivity for a single smear [18]. Other methods include chest radiography, which is
limited in resource-constraint locations [19], and liquid/solid culturing, which requires
suitable levels of biosafety [20]. Diagnosis of latent infection requires a tuberculin skin
test or interferon-gamma release assays. However, both of these tests do not identify
individuals that will progress to active disease [20].
The phenotypic evaluation of clinical isolates, by culturing M. tuberculosis in the
laboratory in the presence of different concentrations of antimicrobials, is traditionally used
to detect drug-resistant strains. The turnover time for these results is extensive, by which
point the patient’s health will have deteriorated [21]. Improvements in molecular diagnostic
testing have revolutionised detection, such as the genotypic test Cepheid GeneXpert
MTB/RIF, which can give a readout in two hours of TB detection and RIF resistance [22].
Additionally, whole-genome sequencing of TB is expanding with support from the WHO
but still relies on culturing samples for weeks and technical methods in preparing genomic
DNA for sequencing [23]. User-friendly and non-laborious detection methods, which are
portable, are required to improve detection time at lower cost.
Experimental modelling of TB has historically helped scientists to discover the pathogenic-
ity, physiology, metabolism, and genetic make-up of the organism. Challenges arising for
researchers studying mycobacteria are the characteristics of slow growth rate, hydrophobic
aggregation of cells in the absence of non-ionic surfactant when grown in culture, and the
need for the containment of aerosols which brings additional safety precautions, including
a biosafety level 3 (BSL-3) facility [7]. Additionally, the investigation of heterogenicity is dif-
ficult in bulk cultures compared with single-cell analysis [24]. Animal models are abundant
for studying TB, such as zebrafish, rabbits, guinea pigs, and mouse models [25]. However,
absent is the ability of each model to represent all aspects of the physiological state of
the cell and tissue environment [25], or they lack the lung immune system entirely [26].
There have been extensive reviews detailing the methods used to experimentally model
this organism in its non-replicating state [27–29]. However, to date, no NRP models mimic
all the physiological features of the bacteria in this condition. Therefore, novel in vitro
experimental models of TB are imperative.
Research groups often use variable types of nutrient media, inoculum starting points,
and reading endpoints, making the standardisation of antimicrobial testing for M. tuberculosis
difficult. Efforts have been made to standardise testing; however, protocols are still time con-
suming [30,31]. TB has shown resistance to antimicrobials, including multidrug-resistant
strains resistant to RIF and INH [1]. Worryingly, extensively drug-resistant TB is increas-
ing, which is resistant to RIF, INH, Fluoroquinolone, and Kanamycin [32]. There is an
urgent need for shorter and more effective treatment regimens, as well as the discovery of
novel compounds. Biomedical engineering approaches such as applied technology have
advanced the field of drug discovery and will continue to develop new research models
with ever more accurate mimicry of human physiology.
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2. Microfluidics
2.1. Technological Advancement of Microfluidics
We require innovative and advanced technology to advance M. tuberculosis research,
such as new high-throughput methods of phenotypic assessment. Advancements in mi-
crotechnology, particularly at the micro and nanoscale, have had wide microbiological
applications. Microfluidics is a rapidly growing field which comprises multidisciplinary ex-
pertise in biology, chemistry, physics, and engineering. A simple definition of microfluidics
is the systematic manipulation of systems that have microscale channels where fluid vol-
umes of nanolitres to attolitres can flow in geometric configurations [33]. Well suited to the
scale of bacteria, microfluidics can produce biological assays in parallel with well-defined,
controllable environmental conditions. Advantageously, the methodological approach of
manipulating fluids opens a pathway to reduce animal models. This review will outline
the field of microfluidics, and discuss the recent use of microfluidic techniques in TB
diagnostics and drug discovery.
2.2. The Physics of Microfluidics
Different physical forces direct the behaviour of a fluid in a system. The essential
behaviour of a hydrodynamic system and the dominant physical effects are typically
analysed by characteristic, dimensionless numbers. These numbers compare the relative
importance of competing forces or may be alternatively described as ratios of characteristic
length, time, or energy scales. The most prominent number in microfluidics is the Reynolds
number, describing the ratio of inertial forces and viscous forces [34]:
Re = ρvL/µ (1)
with mass density (the ratio of a mass of fluid to its volume of the fluid kg/m3) ρ, velocity v,
dynamic viscosity µ, and a characteristic length L describing the dimensions of the system
Due to the capacity of microfluidic systems and the corresponding slow flow velocities,
the value of the number is typically Re < 1, causing laminar flow, a regime also referred to
as Stokes flow, which is a subtype of laminar flow. Mathematically, this regime is governed
by the Stokes equation when Re < 1 [34]:
∇p + f = µ∆v (2)






+ v ∇v has been neglected. This inertia term represents the fluid version of the
acceleration part m dvdt in Newton’s second law vanishing for small Reynolds numbers.
The stationary Stokes equation as shown here in Equation (2) relates the gradient of the
pressure p to the change in velocity v and an external body force f (e.g., a gravitation or
dielectrophoretic force), with ∇ and ∆ being the Nabla and Laplace operator, respectively.
In other words, the pressure gradient and the external body force drive the fluid flow.
However, for some very high-throughput applications operating at high flow velocities, the
assumption of small Re does not necessarily hold true as the regime of “inertia microflu-
idics” is entered. In this regime, the full Navier–Stokes equation including its non-linear
inertia term must be considered.
With the absence of turbulent flow, the mixing of parallel, laminar fluid flows in
microfluidics only occurs by diffusion, which can be a slow process. The Péclet number
(Pe) describes the ratio of the rates of convection and diffusion for suspended objects, and
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where v and w are the flow velocity and microchannel width. The diffusion coefficient






In Equation (4), k is the Boltzmann constant, T is the absolute temperature, and a is
the hydrodynamic radius of the suspended object. For micrometre-sized objects, the effect
of diffusion is generally very small and does not greatly influence overall particle trajectory.
However, as object size decreases, diffusivity increases, meaning that separation efficiency
will be decreased unless flow velocity is increased.
Where mixing is desired, passive mixing can be introduced when designing channel
geometries, such as ridges, network gradient generators, and vortex micromixers. Alterna-
tively, active mixing can be introduced by external energy, for example, electrokinetic forces
and thermal actuation [36]. Active and statistical mass transport can occur in microfluidic
systems [35].
As the geometrical dimensions of a microchannel decrease, the fluidic resistance in-
creases because of friction between the microchannel walls and the body of fluid. Generally,
the surface area to volume ratio becomes larger as the channel geometry becomes more
complex, and so does the fluidic resistance (R), which can limit the fluid flow rate (Q). For





where ∆p is the pressure difference along the microchannel—an increasing R value would
cause a continuing decrease in Q.
The three-dimensional shape of the channel governs the method required to estimate
the fluidic resistance of the microchannel. In a high aspect ratio rectangular microchannel,
whereby channel width or height (h) are larger than the other dimension, the fluidic





where the channel length is l. On the other hand, in a low aspect ratio rectangular mi-

























where r is the radius of the circular cross-section.
2.3. Droplet Microfluidics
The study of multiphase flows, often termed droplet microfluidics, is a subset of the
microfluidics field in which nano- to femtoliter volume droplets can be routinely generated
by drop-making micronozzles in a carrier fluid at production rates exceeding 10 kHz
(Figure 2). Recently, droplet production rates exceeding 1 MHz have been reported [38].
High droplet production rates enable the possibility of undertaking millions of individual
experiments within a single microfluidic device. Further, droplet microfluidic systems
enable the efficient control of droplet volumes, repeatable and reliable droplet manipulation,
high-throughput capability, single-cell analysis capabilities, and can be fully automated.
Their applications include chemical and biological assays [39,40], inorganic chemistry [41],
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and protein crystallisation [42,43]. The reader is referred to recent reviews on various
assays, screens, and studies enabled by droplet microfluidics [44], as well as its applications
in drug discovery, transcriptomics, and molecular genetics [45].




Figure 2. Water-in-oil droplet-generation microfluidics. (A) Production of water-in-oil droplets us-
ing a flow-focusing design. The dispersed phase is squeezed by two counter-streaming flows of the 
carrier phase, forcing drops to form and detach. (B) Droplet generation using T-junction, flow-fo-
cusing geometry and step emulsification. (C) Graph showing that droplet size decreases, and fre-
quency of formation increases with increasing oil flow rate. Figures created on Biorender.com, ac-
cessed on 9 November 2021.  
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For single-cell analysis applications using droplet microfluidics, liquid/liquid emul-
sions comprising a cell-friendly aqueous interior, and a surfactant-stabilised fluorous oil 
are often used. Inclusion of cells in the aqueous, dispersed phase, results in the encapsu-
lation of individual cells within the emulsion. The droplet occupancy number can be con-
trolled by altering the concentration of cells within the dispersed phase and calculated 
using Poisson statistics [46]. To enable such encapsulation, the two immiscible fluids are 
typically flowing and converge within droplet microfluidic systems such that they are 
separated only by their interfaces (Figure 2), giving rise to interfacial tension 𝜸𝒊 between 
the two fluids. The term “surfactant” is a shortening of the term “surface active agent”, 
and describes an amphiphilic molecule, i.e., with different groups having affinities for 
different immiscible phases (water/oil, water/air, oil/air). In droplet microfluidics, surfac-
tants have a basic role: to guarantee that droplets do not coalesce, which is the minimal 
requirement for the use of droplets as microreactors. This amphiphilic property drives 
surfactant molecules to the interface of the two fluids: the surface tension of the interfacial 
layer and interfacial tension between the two phases is decreased. The decrease in surface 
tension is directly influenced by the amount of molecules adsorbed at the interface, as 
given by the Gibbs adsorption isotherm for dilute solutions [47]: 
Figure 2. ater-i - il r l t- eneration microfluidics. (A) Producti n of water-in-oil droplets
using a flow-focusing design. The dispersed phase is squeezed by two counter-streaming flows
of the carrier phase, forcing drops to form and detach. (B) Droplet generation using T-junction,
flow-focusing geometry and step emulsification. (C) Graph showing that droplet size decreases, and
frequency of formation increases with increasing oil flow rate. Figures created on Biorender.com,
accessed on 9 November 2021.
2.3.1. Physics of Droplet Microfluidics
For single-cell analysis applications using droplet microfluidics, liquid/liquid emul-
sions comprising a cell-friendly aqueous interior, and a surfactant-stabilised fluorous oil are
often used. Inclusion of cells in the aqueous, dispersed phase, results in the encapsulation
of individual cells within the emulsion. The droplet occupancy number can be controlled
by altering the concentration of cells within the dispersed phase and calculated using
Poisson statistics [46]. To enable such encapsulation, the two immiscible fluids are typically
flowing and converge within droplet microfluidic systems such that they are separated only
by their interfaces (Figure 2), giving rise to interfacial tension γi between the two fluids.
The term “surfactant” is a shortening of the term “surface active agent”, and describes an
amphiphilic molecule, i.e., with different groups having affinities for different immiscible
phases (water/oil, water/air, oil/air). In droplet microfluidics, surfactants have a basic
role: to guarantee that droplets do not coalesce, which is the minimal requirement for the
use of droplets as microreactors. This amphiphilic property drives surfactant molecules to
the interface of the two fluids: the surface tension of the interfacial layer and interfacial
tension between the two phases is decreased. The decrease in surface tension is directly
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influenced by the amount of molecules adsorbed at the interface, as given by the Gibbs
adsorption isotherm for dilute solutions [47]:





where Γ is the surface concentration, c the surfactant bulk concentration, T is temperature,
R the gas constant, and γ the surface tension.
As surfactant adsorbs to the interface, the interface rigidifies: the loss of mobility
imposes a change in the boundary condition at the interface which slows it down. The
origin of the rigidification is the so-called Marangoni effect: as a drop moves, the surfactant
distribution is non-uniform, with an excess at the rear of the drop [48]. The non-uniform
surface concentration leads to a gradient in surface tension (the surface tension is decreased
at the drop rear) which generates a stress opposed to the flow. When surface tension exists
at the interfacial layer of two phases, with surfactant added to the oil phase, the Marangoni
flow counteracts film drainage to counteract phase mixing, which limits coalescence in
droplet systems.
In conjunction with the interfacial tension between the two phases, complex phe-
nomena arise that are governed by various dimensionless numbers containing the surface
tension. The balance of inertial, viscous, and interfacial tension forces govern droplet for-
mation and subsequent droplet flow. The relationship between the inertial and interfacial
tension forces of the aqueous phase is quantified by the Weber number [34]:
We= ρLv2/γ (10)
which is often paired with the Capillary number [34]:
Ca = µv/γ (11)
when determining droplet formation dynamics. Ca describes the ratio of viscous to in-
terfacial forces and plays an important role in the characterisation of two-phase flows.






describes the relationship between the inertial, viscous, and surface tension forces on
droplet microfluidic flow.
Numerous biomedical applications require materials such as solids or gels, and not
liquids [50]. Solid particles made from polymeric and biological materials are used in drug
delivery [51–54] and hydrogels [55] and are being studied for the encapsulation of cells in
drug studies or for implantation. Many droplet microfluidic systems have been created
to generate solid particles as well as hydrogel beads using various approaches [56–58].
Dissolved polymers add an elastic component to the fluid that further enriches flow
behaviour. The Weissenberg, Deborah, and Elasticity numbers, Wi, De, and El, describe
elastic effects within microfluidic flows due to the presence of deformable materials such as




γ, relates the polymer relaxation






−1. When Wi is large, i.e., approaching 1, the polymer does not have sufficient
time to relax and is deformed significantly. When Wi is small, the polymer has sufficient
time to relax before the flow deforms it significantly, while perturbations to equilibrium
are small.
Another relevant time scale τf low characteristic of the flow geometry may also exist
in droplet microdluidic systems. For example, a channel that contracts over a length l
introduces a geometric time scale τf low = l/v which is required for a polymer to travel
through the channel. Likewise, an oscillatory flow introduces an oscillation time, where
the flow time scale τf low can be long or short compared with the polymer relaxation time
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τp, resulting in a dimensionless ratio known as the Deborah number De = τp/τf low. For
both Wi and De, the equations do not directly depend on γ but are introduced due to the
deformation of objects enclosed by an interface. The polymer relaxation time depends on
γ, however.
As the flow velocity increases, elastic effects become more influential and Wi and De
increase. However, the Reynolds number Re increases too, meaning that inertial effects
can also become more influential. The Elasticity number [34] El = DeRe = τpµ/ρh
2, where
h is the shortest dimension regulating the shear rate, indicates the relative importance of
elastic to inertial effects. Significantly, El is independent of flow rate and depends only on
the geometry and material properties of the fluid.
2.3.2. Device Geometries for Droplet Production
The most common channel geometries used for microdroplet generation include the
T-junction, flow-focusing, and co-flow nozzles, and step-emulsification devices (Figure 2),
each with their own benefits and shortfalls [59,60].
Droplets can be produced hydrodynamically within a T-junction system in the squeez-
ing, dripping, or jetting regimes, whereby Casqueezing < Cadripping < Cajetting [59]. Using
the case of water-in-oil droplet systems as an example, constriction of the oil phase causes
droplet termination/production, i.e., when the aqueous drop fills the geometric nozzle and
causes resistance by pinching the oil flow.
A flow-focusing junction comprises two immiscible phases converging at a cross
junction. The dispersed phase flows towards the junction in a single channel, and the
continuous phase flows towards the junction in two diametrically opposed channels, each
perpendicular to the dispersed phase (Figure 2). The dispersed phase is pinched off by the
two incoming streams of the continuous phase, resulting in the generation of droplets at
the drop-producing nozzle. Different nozzle dimensions influence the range of droplet
volumes possible. These resulting droplets flow away from the junction through a channel
opposite the incoming dispersed phase. By varying the flow rates of each phase, different
sizes of droplets can be created. Whilst more complex than T-junctions, flow-focusing
junctions offer more monodispersed and controllable droplet formation.
Co-flow droplet generators were first described by Cramer et al. [61], and utilise a thin
capillary streaming the dispersed phase into a channel surrounded on two sides (Quasi-2D)
or all sides (3D) [62] by the continuous phase. Quasi-2D junctions are often made using
traditional soft lithography techniques [63], whilst 3D junctions are made by inserting a
tapering glass capillary into a rectangular channel [64].
Step emulsification generators [65] (Figure 2) create droplets by altering the channel
geometry to induce a rapid change in capillary pressure which drives the formation of
droplets. The change in capillary pressure results from a step within the channel which
causes a stream of the dispersed phase to “fall” off a step into the continuous phase. Step
emulsification has benefits over other droplet-formation methods as it can be easily and
massively parallelised. Despite this, the method has some disadvantages, for example, it is
more sensitive to obstructions at the nozzles, which can affect droplet monodispersity [66].
2.3.3. Active Drop Formation
Using an external input of energy can also dictate droplet generation, termed “active
droplet generation” application of an external force can drive the creation of droplets.
There are many techniques for active droplet formation including electrical [67,68], mag-
netic [69], centrifugal [70], optical [71], thermal [72], piezo-electrical [73], and surface
acoustic waves [74]. Active generation methods often require more complex instrumenta-
tion setups and are therefore typically more expensive, and less accessible. Active droplet
generation designs have enabled the regulation of one or more parameters such as droplet
volume [75,76], generation rate [77], and also on/off switching capabilities [74,78], e.g.,
making it possible to produce droplets one at a time as and when required.
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2.3.4. Droplet Sensing and Manipulation
Droplet sensing is important for the identification and/or manipulation of droplets,
and for the automation of sequential droplet activities in microfluidic Lab-on-Chip devices
and/or instruments. When performing time-dependent tasks such as the manipulation of
specific droplets at a specific on-chip location, droplet sensing is crucial to ensure triggered
actions have the correct timing. Further, as the number of manipulation events increases,
the management and automation of droplet manipulation activities needs precise, reliable
information about the location, size, frequency, velocity, and/or content of droplets at
certain locations within the system [79]. Two frequently utilized methods of sensing
droplets in closed microfluidic channels are optical [80–82] and electrical [83–85] detection,
for which the reader is referred to expert reviews [85–87]. To sense the interior contents of
droplets, techniques such as capillary electrophoresis [85], mass spectrometry [88,89], and
Raman spectroscopy [90] have been used in microfluidics, and the reader is also directed
to specialised reviews [87,91] on this topic.
The efficient manipulation of droplets [92], i.e., to perform activities such as droplet
splitting, trapping, fusion, sorting, and/or to manipulate the interior droplet contents, is
important in a range of research and industrial applications across various disciplines,
such as biotechnology, molecular biology and analytical chemistry. Individual droplets can
be manipulated in flow via a variety of techniques, e.g., passively and hydrodynamically
upon careful geometrical design, or, alternatively, using active forces [36]. Many physical
approaches from magnetic [93,94] to electrophoretic [95], dielectrophoretic [96,97], op-
tic [98–100], pneumatic [101] and acoustophoretic [102–104] have been used to manipulate
droplets in a microchannel—the reader is encouraged to visit the prescribed references,
where a technical understanding of some of the various methods described in the literature
can be gained.
2.4. Microfluidic Chip Materials and Microfabrication
Some of the most frequently used materials in microfluidics include thermoplastics,
polydimethylsiloxane (PDMS), inorganic materials such as glass or silicon, paper, and even
devices made by 3D printing, a newer approach to fabrication [105]. The most frequently
used techniques for manufacturing microfluidic devices include micromachining, soft
lithography, embossing, in situ construction, injection molding, and laser ablation—the
reader is referred to expert reviews on such methods [35,37,105–107]. The most suitable
method of device fabrication and material selection often depends on the specific appli-
cation of the device. For example, a prerequisite for microfluidic devices to be used in
biological investigations is that they must of course be biocompatible. Further, chips to be
used for biological applications should be manufactured in a clean room setting to pre-
vent the micro-channel being contaminated by dust or other matter [35]. Thermoplastics
and PDMS are often selected as the material of choice as they are well researched and
microfluidic chip fabrication with these materials is generally lower cost than glass or
silicon [108–110]. Paper microfluidics have extremely low cost and can be used to measure
desired molecules quickly by visual inspection [111–114].
Silicon micromachining was firstly developed for application within the field of micro-
electromechanical systems (MEMS) but was subsequently one of the first techniques to be
used for the microfabrication of microfluidic systems [115]. The well-understood surface
modification properties of silicon, plus the material’s considerable chemical resistance
and ease of design, make silicon a seemingly desirable material for creating microfluidic
devices for biological applications [115]. Despite that, silicon devices are not transparent
to visible light, which means that such devices are not well suited for fluorescence-based
detection or imaging applications [116]. However, making a composite device consisting
of transparent materials such as glass or polymers, which enclose silicon microchannels,
can improve suitability for imaging and fluorescence-based activities [116].
Glass has excellent analysis performance due to its biocompatibility, optical trans-
parency, low fluorescence background, surface stability, and chemical resistance [116].
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However, glass fabrication processes are generally complex, sometimes involving etching
using hazardous substances such as hydrofluoric acid and/or femtosecond laser-based
fabrication procedures [117] which require a high degree of training and safety precau-
tions. Furthermore, high temperature, often in combination with high pressure, is typically
required during bonding. This means that dedicated equipment is often required for
fabrication, and that glass devices suffer from complications in preloading reagents before
assembly, which can be problematic for some biological applications [105].
Soft lithography is one of many techniques used to fabricate microfluidic chips, which
has largely driven the use of PDMS as a commonly used microfluidic device material. By
contact printing, replica modelling and embossing, soft lithography can be used to create
micro-patterns [118]. The procedure includes making a master mould containing a design
made by computer-aided design (CAD). PDMS and a crosslinking agent is poured on top
of the mould and placed in a high-temperature incubator. Once hardened, it is peeled from
the mould to obtain a replica of the master. Access holes are punched for inlet and outlet
tubes and the PDMS is placed on a glass slide and bonded by plasma treatment [119].
Thermoplastics have been extensively researched, refined and used for the mass pro-
duction of high-quality goods, since their initial industrial uses in the 1930s [120]. Various
thermoplastics exist that have been used in microfluidics, including cyclo olefin (co) poly-
mer (COC/COP), polymethyl methacrylate (PMMA), polystyrene, polytetrafluoroethylene
(PTFE), and polyetheretherketone (PEEK)—an excellent review by Gencturk et al. [110]
evaluates the physical properties of thermoplastics used in microfluidics, and the present
state of the development and applications of thermoplastic microfluidic systems used in
cell biology and analyses. PMMA is used as an example, which is widely used in research
laboratories because it is optically transparent and can be manipulated with fabrication
methods such as hot embossing, laser ablation, or precision milling [110]. This material
is useful for small-scale prototyping/production [121]; however, the variability inherent
in PMMA devices made by these fabrication methods often makes them unsuitable for
large-scale commercial production. For example, channel smoothness can be low, and the
heated sealing process can cause deformations which give variability between devices.
COP/COC is generally a better material choice than PMMA due to its biocompatibility,
favourable optical properties, low water uptake, low binding affinity for proteins, rigidity,
strength, and stability [122–125]. Furthermore, COC has excellent moldability, making it a
good material for microfabrication by hot embossing [106].
The use and prevalence of paper-based microfluidics has increased significantly in
recent years due to the compatibility of such devices in point-of-care or point of-use
testing applications, plus their simplicity, fundamental low cost, biocompatibility, and
hydrophilicity [114,126]. Various medical conditions (e.g., pregnancy testing, virus assays,
etc.) can be identified/evaluated using paper microfluidic systems [114]. Fluid flow in
paper devices does not require a driving external force and can instead rely on capillary
force to drive fluid flow, which is caused by the intermolecular force between the fluid
and the porous cellulose matrix of the material [127]. Paper-based diagnostic devices are
simple to use, disposable, low cost, and environmentally friendly [128]. The disposable
nature of paper and paper-derived materials reduces the risk of cross contamination, and
the low cost of these materials allows broader application and more frequent testing.
An emerging microfabrication method which may overcome the limitations of prior
microfluidics fabrication techniques is 3D printing, which enables the prototyping of
devices at lower cost and fabrication time compared to techniques such as soft lithography
or hot embossing [105]. Furthermore, complex 3D structures can be manufactured, without
the need for a cleanroom environment. Three main 3D printing technologies exist: fused
deposition modelling, PolyJet, and stereolithography. Each technology has advantages and
disadvantages—the reader is directed to a specialist review to understand each of these
methods [105].
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3. Recent Application of Microfluidics for TB
3.1. Applications of Microfluidics for Diagnostics and Detecting Drug-Resistant Strains
Employing microfluidics is a promising approach for rapid and cost-effective diagnos-
tics for M. tuberculosis. Detecting the pathogen with robust and reproducible fluidic models
offers capabilities for clinical procedures and scientific exploration. Interestingly, a bacteria
enrichment microfluidic chip and a microfluidic immunoassay chip have detected airborne
M. tuberculosis. Jing and colleagues (2014) validated a method whereby a micro-pump
draws air containing bacteria into the enrichment fluidic chip and then a full immunoassay
reaction is performed on a separate chip. The method offers the potential to accurately
screen M. tuberculosis in the aerosol [129]. Airborne M. tuberculosis currently requires long
cultivation due to the low concentration in air samples. Capturing and directly detecting
airborne M. tuberculosis will aid effective disease prevention and control as there is a re-
quirement to detect samples directly from patients for quicker analysis. The small volume
sizes in microfluidic chip cultivation provides rapid detection at lower sample concentra-
tions. Diagnosing TB, especially in developing countries, requires low-cost point-of-care
technologies. A paper-based microfluidics system detected sputum samples containing
mycobacteria. The system used enabled the decontamination of non-mycobacteria and
storage of the sputum sample [130]. A laser-etched indium tin oxide glass and PDMS
microfluidic chip were used to rapidly detect and quantitate M. tuberculosis with high sensi-
tivity within forty-five minutes. By creating an eight-chamber microfluidic electrochemical
system with real-time loop-mediated isothermal amplification (LAMP), amplification of
three respiratory related infections including M. tuberculosis could be monitored by mea-
suring the electrochemical signal of methylene blue [131]. Here, a microfluidic chip, with
different sample chambers, provides cost- and time-efficient detection which would benefit
clinicians to decide on optimal antibiotic treatments.
Six species of mycobacteria, including nontuberculous species and members of the
M. tuberculosis complex, were detected by combining a closed system of bead-beating,
droplet fluidics, and surface-enhanced Raman spectroscopy. The spectral information
obtained from the vibrational signals of the mycobacterial cell wall component, mycolic
acid, effectively identified the different species. This is a promising step forward for ensur-
ing the correct treatments are administered for the correct infections [132]. Small channel
dimensions enable the manipulation of cell environments and thus can represent improved
biological investigation. A potential method for quantitively detecting M. tuberculosis
in droplet microfluidics was developed by detecting cells that express the endogenous
β-lactamase, BlaC—an enzyme marker naturally expressed by M. tuberculosis. By encap-
sulating a specific fluorescent probe of BlaC and samples of bacterial strains that express
BlaC in droplets, the researchers could calculate the initial concentration of cells based on
fluorescence [133].
Other researchers have combined PCR techniques with microfluidics. Ip et al. (2018)
used a single chip comprising positive and negative reaction chambers, as well as small
liquid handling chambers. They performed isolation of M. tuberculosis H37Ra with mag-
netic beads and differentiation of live/dead bacteria with propidium monoazide dye,
followed by RT-PCR and optical detection within two hours. By measuring the thresh-
old cycle number, a low detection limit of 14 colony-forming units per reaction was
achieved [134]. Besides the above new PCR microfluidic approaches, genetically detecting
M. tuberculosis without the laborious need for PCR amplification has been achieved. For
example, Domínguez et al. (2015) created a micro-cantilever platform, where hydration-
induced stress could identify M. tuberculosis and RIF resistance within 1.5 h [135].
Previously, label-free DNA of M. tuberculosis from clinical isolates was detected by an
integrated system of microfluidics and electrochemical biosensing. The platform consisting
of a monolithic chip and multiwall carbon nanotubes detects M. tuberculosis without the
need for DNA amplification [136]. Another biosensing device was developed to detect
MPT64—an antigen secreted by M. tuberculosis. The protein is a biomarker for actively
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dividing mycobacteria, detected by electrochemical impedance spectroscopy and synthetic
aptamers integrated with a microfluidic chamber [137].
Detecting drug-resistant strains early in the infection will aid clinical decision making
and shorten the time for optimal drug treatment. Sophisticated detection of resistant strains
will also transform drug discovery and innovation within the laboratory. Researchers
detected single-nucleotide polymorphisms between RIF-resistant M. tuberculosis isolates
and susceptible isolates by combining a microfluidic chip with post-PCR high-resolution
melting analysis (HRMA). The authors’ “Light Forge” microfluidic DNA melting-based
TB test showed better performance of melting temperature differences compared to con-
ventional Sanger sequencing, as well as a HRMA device on its own and phenotypic drug
susceptibility testing [138]. Additionally, evidence shows that by incorporating open-chip
microfluidics with padlock probe (PLP) ligation and rolling circle amplification (RCA), a
two-hour assay is achievable for detecting an INH resistance caused by mutations in the
gene (katG) in M. tuberculosis. The lab-on-a-disc platform utilised separate fluidic chambers
for ligation and amplification steps, which provided temperature control [139]. Law et al.
(2018) combined a lab-on-a-disk and recombinase polymerase amplification to fluorescently
detect the pathogen with a sensitivity of 102 colony-forming units per millilitre [140]. Drug-
resistant strains to β-lactams were fluorescently detected using a droplet-based microfluidic
device and a custom 3D particle counter (Figure 3). The microfluidic chip comprised sepa-
rate input channels for bacteria, ampicillin and broth mixture, fluorocillin (a β-lactamase
sensor), and oil to encapsulate single bacteria cells into droplets. Antibiotic-resistant clinical
isolates could grow inside the droplets, detected by fluorescent microscopy [141].
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Investigators are overcoming the challenge of genotyping drug-resista t str i f
the pathogen directly from sputum. Researchers detected and genoty e I a I
resi tance by creating a closed system composed of a microfluidic a lifi
ray [142]. Likewise, the lab-on-a-film platform created by Kukhtin et al. (2020) inte rat
amplification, hybridisation, washing, and imaging. The authors reported . tuberc losis
detection in sputum as 43 CFU/mL; however, future work of this method includes sensi-
tivity investigation [143].
More importantly, it is vital to consider the translation to commercialisation of mi-
crofluidic diagnostic devices. Suitability, such as user-friendliness, portability, and eco-
nomic feasibility, should be addressed at the basic research level. Alternative methods to
fabricate microfluidic devices are by printed circuit board (PCB) technology. A lab-on-a-
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printed circuit board (LoPCB) was integrated with a biosensor system able to detect INFy
for diagnosing TB [144,145]. The simple assay holds promise for developing a handheld,
fully automated device for TB diagnostics. On a successful road to commercialisation,
a lab-on-a-chip assay—VereMTB—has undergone a pilot study. The lab-on-a-chip inte-
grates PCR and microarray to detect the M. tuberculosis complex, RIF and INH resistance,
and NTM in less than 3 h [146,147]. The pilot study states that the detection kit of the
VereMTB system for 124 sputum samples had 97.0% sensitivity and 98.3% specificity for
MTC complex detection, as well as high specificity and sensitivity for RIF and INH re-
sistance detection. On the translational path to commercialisation, the device has shown
the feasibility of efficiently detecting clinical specimens [148]. It can be concluded that
microfluidic chips have been used in combination with PCR, biosensors, and microscopy
techniques for detecting TB infection and resistant strains (Table 1).
Table 1. Summary of current microfluidic applications for diagnostics and detection of M. tuberculosis.
Sample Devices Applied Applications
Direct bodily fluids
Detection of clinical isolates,
model organisms,
attenuated strains















3.2. Applications of Microfluidics for TB Drug Discovery
Microfluidic technologies have been developed for portable and disposable TB diag-
nostics, but more recently there have been attempts to bridge these microfluidic techniques
with conventional antibiotic drug discovery for TB. A microfluidic system in combina-
tion with microspheres (comprising M. tuberculosis, peripheral blood mononuclear cells,
and type I collagen) was achieved for the pharmacokinetic modelling of antibiotics. Af-
ter establishing the 3D granuloma microsphere model, the fluidic system was used to
mimic the pharmacokinetics of that seen in vivo by altering various concentrations of
RIF over time. They observed fluctuations in killing over time compared with fixed an-
tibiotic concentrations [149]. This method establishes a close resemblance to the range
of drug concentrations over time in the body when a patient is exposed to antibiotics
due to the adsorption, distribution, metabolism, and excretion (ADME) properties of the
drugs administered.
Interestingly, Aldridge et al. (2012) studied heterogeneity between mycobacterial cell
growth rates. Using a microfluidic chamber with live-cell imaging, they measured the
elongation rates of single cells and concluded that due to the unipolar manner of bacteria
growth, this causes heterogeneity in elongation growth rate. They selected the microfluidic
chamber as it advantageously allows single cells to grow in the shallow chamber with
fresh nutrient media diffusing across the channel. This permitted the ideal imaging of five
generations of bacteria for growth studies [150]. A subsequent study using this model
compared growth parameters and treatment responses to RIF. The microfluidic device
cultured and imaged green fluorescent M. smegmatis cells. RIF was dispersed into the
mixing device by a syringe pump to detect RIF-tolerant and -susceptible cells. The authors
concluded an association of RIF tolerance with elongated cell length and advanced growth
pole age at birth [151]. Additionally, using Aldridge’s microfluidic model and time-lapse
microscopy, additional research explores the mechanisms by which heterogeneity has an
effect on drug action. The authors found that a single gene, lamA, permits asymmetrical
growth in replicating mycobacterial cells. M. tuberculosis cells deficient in lamA were more
susceptible to RIF than wild-type bacteria. The authors suggest that by targeting lamA,
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scientists could in the future reduce the diversity in mycobacterial populations and thus
eliminate persistence [152].
Time-lapse microscopy combined with microfluidics is proving useful to study popu-
lation heterogeneity in bacteria strains. A group who are investigating a microfluidic appli-
cation for tuberculosis previously used a microfluidic chamber to monitor M. smegmatis
growth dynamics in real time. The visualisation of chromosome and replisome tracking
were studied using time-lapse microfluidic microscopy (TLMM) [153–155]. After studying
chromosome organisation, the authors then showed changes in cell replication and mor-
phology following the addition of novobiocin, nalidixic acid, and griselimycin which are
all replication-altering drugs [155]. The ability to study single-cell growth dynamics and
changes in the replication complex upon the addition of antimicrobials will aid finding
drug mechanisms of action for future drug discovery. Individual cell analysis was demon-
strated using a confocal laser-scanning microscope and a microfluidic device. This allowed
the growth dynamics and antibiotic killing of fluorescently labelled M. smegmatis to be
measured in real time [156]. Drug mechanisms of action can also be found by monitoring
metabolic changes induced by antibiotics by microfluidics. Baron et al. (2020) incorpo-
rated a microfluidic platform and wavelength-modulated Raman spectroscopy to trap live
mycobacteria and analyse them optically. They discovered that monitoring the metabolic
changes over time of bacteria induced by INH could be used to study different stress
conditions in the future [157].
In addition to the previously mentioned imaging/microfluidic approaches, microflu-
idic live-cell imaging was combined with time-lapse microscopy to investigate the antimi-
crobial activity of peptoids (oligo-N-substituted glycines). The study concluded that the
investigative molecules’ mechanism of action disrupted the cell membrane shown by the
increased rate of uptake of propidium iodide [158].
Drug susceptibility testing utilising microfluidics has been attempted, which is faster
than conventional approaches. M. tuberculosis has been immobilised in an agarose matrix
and introduced to antibiotics which diffuse into the agarose on a microfluidic chip [159].
The agarose enables single cells that are being monitored by time-lapse imaging to remain
stationary compared to liquid cultures. Minimal inhibitory concentrations (MIC) were
determined by day 9 of experiments compared with weeks of conventional methods. Sub-
sequent publications of this “Disc Agarose Channel (DAC)” system provided optimisation
and validation (Figure 4A). The system was not sensitive to the initial inoculum effect, and
MIC experiments with first- and second-line antimicrobials were achieved in 7 days [160].
Performance was then compared to conventional drug susceptibility testing when the
microfluidic chip was optimised for commercial use and proved high agreement rate of
97.8% with a faster turnover time. A unique advantage of the DAC system is that it reduced
TB leakage by a sealing film and locking lid, and serial dilution was not required, providing
safety for laboratory researchers.
Investigating the mechanism of antibiotic tolerance was demonstrated using wild-type
and msm2570::Tn mutants of M. smegmatis. Single cells were studied using microfluidics
and time-lapse microscopy and provided evidence that the mutant strain was more tolerant
to INH compared to the wild-type strain. This current example is proof that microfluidics
can achieve an improved understanding of resistance mechanisms of mycobacteria to
antibiotics and aid the discovery of new antimicrobials [161].
The advancement of 3D models such as organ-on-a-chip has provided researchers the
tools to study drug actions with more efficient in vitro models. This could reduce the use
of animal models. For example, a lung-on-a-chip model was used to mimic the alveolar
lung environment of early TB infection. A porous membrane creates an air–liquid interface
of alveolar and vascular compartments and was then used to study the effect of pulmonary
surfactant on mycobacteria infection of alveolar epithelial cells and macrophages. Utilis-
ing time-lapse microscopy, the model not only mimicked the host–pathogen interaction
but also found that pulmonary surfactants had a protective role against TB, as shown by
increased intracellular bacterial growth when cells lacked surfactants [162].This lung-on-a-
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chip model could aid drug discovery screening, which is more physiologically relevant.
Previous studies have shown the utilisation of microfluidics for creating in vitro models
of TB granulomas. “Stacks” is a previously cited microfluidic co-culture platform which
enables extracellular signalling between different layers of cell types [163]. Building on
this platform, an in vitro model was shown of an internal mycobacterial infection and its
surrounding environment (Figure 4B). They used the model for soluble factor signalling
studies, and further utilisation could explore the various immune signalling pathways of
TB pathology [164]. Moreover, applications of engineered oxygen sensing in cultures could
pave the way for controlling oxygen content when optimising new models of NRP TB. Mea-
suring the concentration of oxygen in picodroplets has been demonstrated. Researchers
successfully measured oxygen concentration against optical density (600 nm) of Escherichia
coli and Mycobacterium smegmatis by utilising optical sensor nanoparticles. The nanoparti-
cles had a phosphorescent indicator dye embedded in poly (styrene-blockvinylpyrrolidone)
nanobeads and were easily integrated into a droplet device [165]. Monitoring analytes or
conditions which influence bacterial growth is important in microbiology research and
could be advanced by using microfluidic “stochastic confinement” droplets.
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3.3. Future Application of Drug Screening in Microdroplets
The feasibility of using encapsulation technology to rapidly detect and enumerate
individual microorganisms in patient samples has been demonstrated [166]. Effective
control of TB transmission in vulnerable population groups is dependent on the rapid iden-
tification of the infectious agent and its drug susceptibility. M. bovis BCG and M. smegmatis
were encapsulated in gel microdroplets, with a mean diameter of 25 µm, along with flow
cytometry as a model system to investigate the efficacy of encapsulation and the detection
of clonal growth by flow cytometry [167]. The characteristic slow growth of these microor-
ganisms, as well as the small number found in most clinical samples, has made the direct
detection of TB bacilli by biochemical and immunological methods difficult. Use of gel
microdroplet encapsulation in combination with flow cytometry could reduce the time
required to evaluate clinical samples and establish effective treatment regimens.
One advantage of droplet microfluidics is the approach of “stochastic confinement” [168].
When single cells are confined in microdroplets of small volume, the loading is defined
by Poisson statistics. When less than one bacterium is encapsulated per microdroplet, the
resultant library of droplets is either singly occupied or empty. As detection time is propor-
tional to the plug volume, then the random statistical probability of confinement effectively
increases the cell density and subsequently reduces the time required for their detection.
Using a microfluidic hybrid method, a variety of antibiotics were screened against a single
bacterial sample. E. coli cells have been encapsulated in agarose monodisperse micropar-
ticles, approximately 30 µm diameter, using a flow-focusing microfluidic chip. Both the
MIC for RIF and the sorting of spontaneous mutants by fluorescence-activated cell sorting
(FACS) was demonstrated and characterised by DNA sequencing [169]. Building on this
previous work, FACS screening of gel microdroplets has been shown, in which the bacterial
pathogen Staphylococcus aureus is co-cultured with a recombinant host—Saccharomyces
cerevisiae or E. coli, which are capable of secreting biocatalytic antibiotics and/or secondary
metabolites from a metagenomic library [170]. The gel microdroplets (25 pL) are of a
size compatible with conventional FACS instruments at 3000 droplets/second, allowing
the proof-of-concept selection of antibiotic-secreting yeast from a vast excess of negative
controls [170].
The frequency of resistance (FOR) of INH- and EMB-resistant mutants has been mea-
sured to be in the order of 1 × 10−7–1 × 10−9, respectively. Hence, to obtain a reasonable
number of mutants (10–100 for DNA sequencing), at least 109 bacteria would have to be
screened. A label-free high-throughput method was previously reported for screening up
to 1 × 109 bacteria for AMR in water-in-oil picolitre-volume droplets (picodroplets); using
Poisson statistics, the occupancy per picodroplet was 100 bacteria (E. coli HS151) [171].
From roughly 10 million picodroplets that were screened against fusidic acid, 103 droplets
with drug-resistant hits were sorted. The recovered cells were grown on agar containing
fusidic acid (10 µg/mL) and the mutant colonies submitted for DNA sequencing. The
flexibility of alginate hydrogel beads (65 nL, 500 µm diameter) have the advantage of being
able to be shuffled back and forth between the hydrophobic and hydrophilic phase. Schmitt
et al. (2019) demonstrated the co-encapsulation of a library of Lactococcus lactis cells pro-
ducing antimicrobial lanthipeptides with approximately 150 sensor strain cells, Micrococcus
flavus, then back to the hydrophilic phase for the activation of lanthipeptide production,
and back to the hydrophobic phase for incubation and to prevent lanthipeptide crosstalk
between the microdroplets [172]. Finally, these nanolitre reactors (nLRs) were demulsified
and stained with the fluorescent dye SYTO 9, and nLRs with no or only very little biomass,
indicating the effective prevention of sensor strain growth, were isolated. Although this
has yet to be carried out with mycobacteria, this technology holds considerable promise to
screen antimicrobials against M. tuberculosis at the single cell level.
4. Discussion and Future Perspectives
Microfluidics is gradually transforming TB research. The application of fluidic devices
in TB diagnostics, microbiological research, and drug discovery has proven the power
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of this technique in improving throughput and sensitivity and reducing dependence on
animal models. Combining microfluidics with diagnostics and detection is ahead of the
field compared to drug discovery. Chips were used in combination with PCR, biosensors,
and microscopy techniques for detecting TB infection and resistant strains. We can now
easily observe mycobacterial cell morphology when coupling microfluidics with imaging
techniques which could aid our understanding of mycobacteria heterogeneity. Overall,
it was found that the materials and methods used to fabricate microfluidic chips for TB
investigation were biocompatible and cheap, making them suitable for long culture times
and use in low-resource settings.
Droplet fluidics is still rapidly evolving and will continue to grow with the success
of its applications. There is a potential to incorporate novel droplet systems for studying
biological processes for TB, such as cultivation vessels, investigating environmental stimuli,
and the killing activity of antibacterials due to the ability of droplet sorting, injection,
incubation, and mixing [173]. Droplets allow for the compartmentalisation of single cells
from high-density cultures and the manipulation of cell environments. Thereby, droplets
could prevent competition for nutrients or space among mycobacteria, allowing the slow-
growing species to proliferate. From this literature review, it is noted that the use of
droplet fluidics has not been fully applied for TB. To our knowledge, three studies have
shown droplet applications in mycobacteria including detection [133], differentiation of
species [132], and detecting resistant strains to antibiotics [141]. As evidenced by the
ground-breaking research within the field of microfluidics and its use for drug discovery,
undoubtedly there is an increased outlook of standardised microfluidic devices to test
antimicrobials against mycobacteria and to discover their mechanisms of action. As other
studies have investigated the drug screening of different microorganisms in microdroplets,
there is scope and a gap in the literature for combining droplet fluidic technology at the
picolitre scale with TB drug discovery. Microfluidic models are yet to replicate the NRP
state of the mycobacteria and carry out antibiotic susceptibility testing in a standardised
and high-throughput manner. There is an opportunity to create a new, faster, and more
sensitive method of antimicrobial susceptibility testing which is more clinically relevant to
the NRP state of the bacterium.
Future research should focus on translating these laboratory platforms into commer-
cial application for industry and clinical practice. Commercial products of single-cell
droplet platforms have been successful, such as inDrop, Drop-seq, and 10× Genomics [173].
Interestingly, as previously mentioned, a droplet system is on the path to commercial-
isation for TB resistance detection [148]. Challenges for the commercialisation of these
novel platforms include translation, user-friendliness, portability, and economic feasibility.
Interdisciplinary collaboration has facilitated these advancements, usually involving bi-
ologists and engineers and their respective stakeholders. Challenges to overcome in this
multidisciplinary field include the scale-up of testing and parallelisation for industry usage.
Furthermore, transfer of “know-how” between designers and end users is imperative. With
the miniaturisation of biological assays, more robust data points are obtainable and may
need bioinformatic expertise and sophisticated computational tools. Machine learning has
the ability to learn from high-throughput data. It has previously been used in TB chest
X-ray diagnosis, which helps to prevent the overdiagnosis or underdiagnosis of TB made
by variations in X-rays [174]. Converging microfluidic analysis with machine learning
could provide high-throughput accuracy and prediction models in the field of TB [175].
Machine learning algorithms made from large datasets obtained from microfluidic chip ar-
rays will possibly predict antimicrobial resistance to tuberculosis. This would aid empirical
treatment to find the right treatment option for the patient at the right time [176,177]. This
provides an opportunity for paving a “precision medicine”-based therapy option when
deciding what drugs to give to patients. With the rapid detection of resistant clinical strains
in hospital environments, patients could receive the correct choice of antimicrobial at the
correct time, eliminating the infection faster and reducing antimicrobial resistance.
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It is encouraging to highlight the breadth of research utilising microfluidics and
multidisciplinary collaboration for furthering our understanding of TB, its diagnosis, and
how best to manage it.
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in Action: Exploiting Time-Lapse Microfluidic Microscopy as a Tool for Target-Drug Interaction Studies in Mycobacterium.
Antimicrob. Agents Chemother. 2019, 63, e00739-00719. [CrossRef]
156. Golchin, S.A.; Stratford, J.; Curry, R.J.; McFadden, J. A microfluidic system for long-term time-lapse microscopy studies of
mycobacteria. Tuberculosis 2012, 92, 489–496. [CrossRef]
157. Baron, V.A.-O.; Chen, M.A.-O.; Hammarstrom, B.A.-O.; Hammond, R.J.H.; Glynne-Jones, P.A.-O.; Gillespie, S.H.; Dholakia, K.
Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform. Commun. Biol. 2020, 3, 236. [CrossRef]
158. Khara, J.S.; Mojsoska, B.; Mukherjee, D.; Langford, P.R.; Robertson, B.D.; Jenssen, H.; Ee, P.L.R.; Newton, S.M. Ultra-Short
Antimicrobial Peptoids Show Propensity for Membrane Activity Against Multi-Drug Resistant Mycobacterium tuberculosis.
Front. Microbiol. 2020, 11, 417. [CrossRef] [PubMed]
159. Choi, J.; Yoo, J.; Kim, K.J.; Kim, E.G.; Park, K.O.; Kim, H.; Kim, H.; Jung, H.; Kim, T.; Choi, M.; et al. Rapid drug susceptibility test
of Mycobacterium tuberculosis using microscopic time-lapse imaging in an agarose matrix. Appl. Microbiol. Biotechnol. 2016, 100,
2355–2365. [CrossRef]
160. Jung, Y.G.; Kim, H.; Lee, S.; Kim, S.; Jo, E.; Kim, E.G.; Choi, J.; Kim, H.J.; Yoo, J.; Lee, H.J.; et al. A rapid culture system uninfluenced
by an inoculum effect increases reliability and convenience for drug susceptibility testing of Mycobacterium tuberculosis. Sci.
Rep. 2018, 8, 8651. [CrossRef] [PubMed]
161. Elitas, M.; Dhar, N.; McKinney, J.D. Revealing Antibiotic Tolerance of the Mycobacterium smegmatis Xanthine/Uracil Permease
Mutant Using Microfluidics and Single-Cell Analysis. Antibiotics 2021, 10, 794. [CrossRef] [PubMed]
162. Thacker, V.V.; Dhar, N.; Sharma, K.; Barrile, R.; Karalis, K.; McKinney, J.D. A lung-on-chip model of early\textit Mycobacterium
tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. eLife 2020, 9, e59961.
[CrossRef] [PubMed]
163. Yu, J.; Berthier, E.; Craig, A.; de Groot, T.E.; Sparks, S.; Ingram, P.N.; Jarrard, D.F.; Huang, W.; Beebe, D.J.; Theberge, A.B.
Reconfigurable open microfluidics for studying the spatiotemporal dynamics of paracrine signalling. Nat. Biomed. Eng. 2019, 3,
830–841. [CrossRef] [PubMed]
Microorganisms 2021, 9, 2330 24 of 24
164. Berry, S.B.; Gower, M.S.; Su, X.; Seshadri, C.; Theberge, A.B. A Modular Microscale Granuloma Model for Immune-
Microenvironment Signaling Studies in vitro. Front. Bioeng. Biotechnol. 2020, 8, 931. [CrossRef]
165. Horka, M.; Sun, S.; Ruszczak, A.; Garstecki, P.; Mayr, T. Lifetime of Phosphorescence from Nanoparticles Yields Accurate
Measurement of Concentration of Oxygen in Microdroplets, Allowing One To Monitor the Metabolism of Bacteria. Anal. Chem.
2016, 88, 12006–12012. [CrossRef]
166. Weaver, J.C.; Williams, G.B.; Klibanov, A.; Demain, A.L. Gel Microdroplets: Rapid Detection and Enumeration of Individual
Microorganisms by their Metabolic Activity. Bio/Technology 1988, 6, 1084–1089. [CrossRef]
167. Ryan, C.; Nguyen, B.T.; Sullivan, S.J. Rapid assay for mycobacterial growth and antibiotic susceptibility using gel microdrop
encapsulation. J. Clin. Microbiol. 1995, 33, 1720–1726. [CrossRef]
168. Boedicker, J.Q.; Li, L.; Kline, T.R.; Ismagilov, R.F. Detecting bacteria and determining their susceptibility to antibiotics by stochastic
confinement in nanoliter droplets using plug-based microfluidics. Lab Chip 2008, 8, 1265–1272. [CrossRef] [PubMed]
169. Eun, Y.J.; Utada, A.S.; Copeland, M.F.; Takeuchi, S.; Weibel, D.B. Encapsulating bacteria in agarose microparticles using
microfluidics for high-throughput cell analysis and isolation. ACS Chem. Biol. 2011, 6, 260–266. [CrossRef] [PubMed]
170. Scanlon, T.C.; Dostal, S.M.; Griswold, K.E. A high-throughput screen for antibiotic drug discovery. Biotechnol. Bioeng. 2014, 111,
232–243. [CrossRef] [PubMed]
171. Liu, X.; Painter, R.E.; Enesa, K.; Holmes, D.; Whyte, G.; Garlisi, C.G.; Monsma, F.J.; Rehak, M.; Craig, F.F.; Smith, C.A. High-
throughput screening of antibiotic-resistant bacteria in picodroplets. Lab Chip 2016, 16, 1636–1643. [CrossRef] [PubMed]
172. Schmitt, S.; Montalbán-López, M.; Peterhoff, D.; Deng, J.; Wagner, R.; Held, M.; Kuipers, O.P.; Panke, S. Analysis of modular
bioengineered antimicrobial lanthipeptides at nanoliter scale. Nat. Chem. Biol. 2019, 15, 437–443. [CrossRef] [PubMed]
173. Suea-Ngam, A.; Howes, P.D.; Srisa-Art, M.; deMello, A.J. Droplet microfluidics: From proof-of-concept to real-world utility?
Chem. Commun. 2019, 55, 9895–9903. [CrossRef] [PubMed]
174. Sathitratanacheewin, S.; Sunanta, P.; Pongpirul, K. Deep learning for automated classification of tuberculosis-related chest X-Ray:
Dataset distribution shift limits diagnostic performance generalizability. Heliyon 2020, 6, e04614. [CrossRef]
175. Galan, E.A.; Zhao, H.; Wang, X.; Dai, Q.; Huck, W.T.S.; Ma, S. Intelligent Microfluidics: The Convergence of Machine Learning
and Microfluidics in Materials Science and Biomedicine. Matter 2020, 3, 1893–1922. [CrossRef]
176. Feretzakis, G.; Sakagianni, A.; Loupelis, E.; Kalles, D.; Skarmoutsou, N.; Martsoukou, M.; Christopoulos, C.; Lada, M.;
Petropoulou, S.; Velentza, A.; et al. Machine Learning for Antibiotic Resistance Prediction: A Prototype Using Off-the-Shelf
Techniques and Entry-Level Data to Guide Empiric Antimicrobial Therapy. Healthc. Inform. Res. 2021, 27, 214–221. [CrossRef]
177. Feretzakis, G.; Loupelis, E.; Sakagianni, A.; Kalles, D.; Lada, M.; Christopoulos, C.; Dimitrellos, E.; Martsoukou, M.; Skarmoutsou,
N.; Petropoulou, S.; et al. Using Machine Learning Algorithms to Predict Antimicrobial Resistance and Assist Empirical Treatment.
Stud. Health Technol. Inform. 2020, 272, 75–78. [CrossRef]
